Topical SGX302 for Mild-to-Moderate Psoriasis

NCT05442190 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
15
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Soligenix